Arexvy

Arexvy is a recombinant respiratory syncytial virus (RSV) vaccine, originally developed by GlaxoSmithKline, indicated for preventing lower respiratory tract disease caused by RSV in adults aged 60 and older; it works by prompting an immune response to the virus's F protein, and common post-vaccination reactions include local injection-site pain and fatigue, with caution advised for pregnant women, immunocompromised individuals, and those with acute febrile illness. This listing is offered by VuRoyal (SuQian) Pharmaceutical Company LLC, which does not manufacture the vaccine directly, and covers North America, Central/South America, and Western and Eastern Europe.